phosphodiesterase


Also found in: Dictionary, Wikipedia.
Related to phosphodiesterase: Phosphodiesterase inhibitors

phosphodiesterase

/phos·pho·di·es·ter·ase/ (-di-es´ter-ās) any of a group of enzymes that catalyze the hydrolytic cleavage of an ester linkage in a phosphoric acid compound containing two such ester linkages.

phosphodiesterase

(fŏs′fō-dī-ĕs′tə-rās′, -rāz′)
n.
Any of a class of enzymes that catalyze the hydrolytic cleavage of phosphodiester bonds and are important in breaking down cyclic AMP, cyclic GMP, and nucleic acids.

phosphodiesterase

(fos″fō-dī-es′tĕ-rās″, -rāz″),

PDE

An enzyme critical for the breakdown of cyclic adenosine monophosphate.

phosphodiesterase

a group of enzymes that catalyze the hydrolysis of a phosphodiester.
References in periodicals archive ?
Title: The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia
Learn How to Profile Phosphodiesterases Using the AMP/GMP TR-FRET Assay:
Effects of sildenafil on the relaxation of human corpus cavemosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.
The lead programme, RPL554, is an innovative dual phosphodiesterase (PDE) 3 and 4 inhibitor with both bronchodilator and anti-inflammatory properties.
Several alternative theories concerning the action of xanthines have been proposed in addition to phosphodiesterase inhibition.
Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor-induced vascular lesions in rats.
Beyond that, the phosphodiesterase type 5 inhibitors (sildenafil, vardenafil, and tadalafil are the three now available commercially) have well demonstrated efficacy in treating erectile dysfunction, Dr.
The pill, which has taken America by storm, works by stopping an enzyme called phosphodiesterase, allowing more blood to flow to the penis.
Viagra, generically known as sildanafil citrate, is a phosphodiesterase type 5 inhibitor that improves blood flow to the penis.
K-134 is a novel selective inhibitor of phosphodiesterase (PDE) activity (type 3A/3B) that has anti-platelet effects, and is anticipated to improve walking performance in patients with intermittent claudication (IC).
Poster number 231, entitled: "The Dual Phosphodiesterase 3 and 4 Inhibitor, RPL554, Enhances Forskolin-Stimulated, CTFR-Dependent Currents in Cystic Fibrosis Airway Epithelia" investigated the effect of RPL554, an inhaled dual PDE3/4 inhibitor, on the Cystic Fibrosis Transmembrane conductance Regulator (CFTR), an anion channel that is mutated in Cystic Fibrosis (CF).
An oral agent that inhibits the activities of phosphodiesterase and thromboxane, NM-702 is a candidate for the treatment of arteriosclerosis obliterans.

Full browser ?